SBIR/STTR Research Award

SBIR Phase I: Expressing bacterial luciferase in zebrafish as an innovative new tool for data-intensive, higher-throughput drug discovery

Award identifier c677835833ece41dbf3d0110b49b960511fe7b726584ad5237df658bed91a95dAwarding agency National Science Foundation

Award amount

$150,000

Program and phase

SBIR · Phase I

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
490 BIOTECH INC
Proposal award date
2014-01-01
Contract end date
2014-12-31
UEI
L2T9XGZ1JUL5
Solicitation number
Not reported
Topic code
BC

Research abstract

This Small Business Innovation Research (SBIR) Phase I project proposes to develop self-generated bioluminescence in zebrafish to create improved models for new drug discovery, therapeutic testing, and biomedical disease imaging. Zebrafish share many common anatomical, developmental, and physiological features with humans, including disease pathologies and drug metabolism effects, and serve as ideal models for understanding how drugs and other chemicals facilitate disease management as well as cause harm through unidentified side-effects. The objectives of this research effort are to express the bacterial luciferase genes in zebrafish to create autonomously bioluminescent zebrafish models capable of delineating the biological and metabolic effects of human/drug interactions. The self-generation of bioluminescence in zebrafish is anticipated to enable higher-throughput screening assays to generate data in real time, faster, and in larger quantities than previously possible, thereby accelerating the pace of new drug discovery while reducing associated costs. The broader impact/commercial potential of this project, if successful, will be to improve pharmaceutical drug discovery and efficacy testing, and to facilitate better human and animal disease management. Small and rapidly growing zebrafish function to reduce space and maintenance requirements, thus lowering the costs associated with pharmaceutical research and new drug discovery while decreasing the industry's reliance on animals for laboratory testing. Scientific and technological understanding in the biomedical fields will be enhanced due to massively data-rich higher-throughput screening for drug action and disease therapies. Ancillary to these applications will be similar zebrafish screening strategies relevant to the detection and surveillance of chemical contaminants in the environment for the assurance of clean and safe water to better meet growing societal needs.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

11 SBIR/STTR records share this UEI (2013–2019). Reported award amounts total $5,038,908. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Agriculture

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.